Table 3

Associations of the antibodies to change in SHS (total score, erosion score and joint space narrowing score) between baseline and 10-year follow-up

Univariate analysesMultivariate analyses*
Total scoreErosion scoreJoint space narrowing scoreTotal score
β (95% CI)p ValueR2β (95% CI)p ValueR2β (95% CI)p ValueR2β (95% CI)p ValueR2
Anti-CCP+24.9 (15.4 to 34.4)<0.010.1810.9 (6.4 to 15.4)< (3.6 to 13.8)<0.010.0613.3 (0.8 to 25.9)0.040.21
Anti-MCV+29.6 (20.3 to 38.8)<0.010.2512.9 (8.4 to 17.4)<0.010.2110.6 (5.4 to 15.7)<0.010.0919.5 (7.3 to 31.6)<0.010.30
  • Results from univariate and multivariate linear regression.

  • *Adjusted for sex, age, ESR, RF status, PTPN22 1858T and SE according to previous findings in the same cohort.

  • ACPA, anti-citrullinated peptide antibody; CCP, cyclic citrullinated peptide; ESR, erythrocyte sedimentation rate; JSN, joint space narrowing; MCV, mutated citrullinated vimentin; PTPN22, protein tyrosine phosphatase, non-receptor type 22; RF, rheumatoid factor; SE, shared epitope; SHS, van der Heijde modified Sharp score.